Table 3.

Neutralization of vaccinee and control isolates by MAbs and CD4IgG2

IsolateDescriptiona90% infectious dose neutralization titer (μg/ml) with:
CD4IgG2MAb:
IgG1b122G12b2F5447/52-D
AD6Acute126.6>50<2>50
AD13Acute>50>50>509.7>50
AD60Acute39>50>509.148
AD75Acute359.3>5040NDc
AD74Acute49>50>5040ND
C18Placebo48>50>5046>50
C06Early MN45411346>50
C04Early SF-2d 46>502.746>50
C09Early SF-2d 9.35.9<225>50
C07Late MN3630>5031>50
C10Late MN>50>501846>50
C11Late MN7.34.2>50831
C17Late MN<27.6<23545
C13Late SF-245>50 <2 41>50
C20Late SF-25.1>50>509.1ND
C21Late SF-2419>5026ND
pC04Partner for C04>50>501047ND
pC13Partner for C1344>50 >50 8>50
  • a Acute denotes isolates obtained from nonvaccinated individuals with presumed primary infection. The designations of early and late isolates are based on the number of immunizations each individual received prior to infection (see Fig. 1and 2).

  • b Apparently discrepant neutralization titers are highlighted.

  • c ND, not determined.

  • d Early-infection isolates; i.e., there was no antibody response to vaccine prior to virus isolation.